AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 133 min read$JNJ

Johnson & Johnson's Orthopedic Unit Sale Talks with Apollo Globa

Apollo Global Management is in talks to acquire Johnson & Johnson's (JNJ) DePuy Synthes orthopedic division for around $20 billion. JNJ, trading at $265.58, is seen as 37.4% overvalued with a GF Value of $193.26. The company has a strong dividend yield of 1.99% and a GF Score of 83, indicating robust financial health. Insiders have sold $67.8 million in shares recently.

Original reporting
gurufocus.com
Published Sep 13, 2026, 7:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 7:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$JNJ
Bearish
high confidence
Mentioned
$JNJ
Relevance
9/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$JNJBearishHigh
01

Why it matters

The deal could reshape JNJ’s revenue profile and affect med‑tech valuations; investors may react with short‑term weakness but could benefit from cash proceeds later.

02

Market read

A large‑scale M&A talk involving a $20 billion orthopedic business could shift sector dynamics and influence JNJ’s valuation.

03

What to watch

Potential tax benefits, strategic partnership opportunities for DePuy Synthes under new ownership, and possible use of proceeds for share buybacks.

Relevance 9/10Novelty 9/10Timing: today (Sep 13)

Background

Johnson & Johnson’s orthopedic unit DePuy Synthes is reported to be in sale talks with Apollo Global Management for about $20 billion, amid broader portfolio streamlining.

Company-level read

Ticker impact

$JNJBearishHigh confidence
Context

Apollo Global Management is negotiating to acquire Johnson & Johnson's DePuy Synthes orthopedic division for approximately $20 billion.

Expected impact

Downward pressure on JNJ stock, possible 2‑4% dip as investors reassess earnings outlook.

Evidence & confidence

A $20 B sale of a core orthopedic business is material; the market will price in reduced revenue and integration risk.

Market effects

Sector

Signals consolidation in the medical‑device sector, prompting reassessment of other med‑tech peers.

Regional

May weigh on US healthcare and pharma indices as JNJ’s core business mix changes.

Global

Highlights growing interest from private‑equity firms in large‑cap health‑care assets worldwide.

Counterpoint

What could challenge this read

The divestiture could unlock cash, reduce debt, and sharpen JNJ’s focus on higher‑growth pharma, potentially supporting the stock long term.

Key entities

  • Company
    Johnson & Johnson

    US healthcare conglomerate considering sale of its DePuy Synthes division.

  • Private‑equity firm
    Apollo Global Management

    Potential acquirer of DePuy Synthes.

  • Business unit
    DePuy Synthes

    JNJ’s orthopedic division targeted for sale.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 22
$JNJMedAI 8/10

J&J Reports New Data on Atrial Fibrillation Devices

Johnson & Johnson presented new clinical data for its atrial fibrillation devices at the Asia Pacific Heart Rhythm Society 2026 meeting. The Varipure device showed 100% acute procedural success in 225 patients, while 82.5% of 136 Omnypulse patients had no recurrence after 12 months.

ocbj.com2 min
OCT 22
$JNJMedAI 8/10

Why is Johnson & Johnson stock rallying today?

Johnson & Johnson (JNJ) stock rose 3.0% after presenting positive clinical data for its pulsed field ablation technology at a conference. The VARIPURE and Omny-IRE studies showed high success rates and low adverse events. Analysts raised price targets, with Wells Fargo setting a new target of $287. Despite a broader market decline, JNJ's stock gained due to its defensive appeal and strong pharmaceutical segment growth.

investing.com2 min
OCT 22
$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Presents Breakthrough Atrial Fibrillation Stud

Johnson & Johnson (JNJ) presented positive clinical trial results for atrial fibrillation treatments at a conference. The VARIPURE study showed 100% procedural success, while Omny-IRE achieved 82.5% success in preventing arrhythmia recurrence. JNJ has a 2.06% dividend yield, 70% payout ratio, and 4.9% dividend growth over three years. The stock trades 32.5% above its GF Value™, with insiders selling $150.7M in shares over the past year.

gurufocus.com3 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026

Johnson & Johnson (JNJ) presented data from VARIPURE and Omny-IRE studies at APHRS 2026. VARIPULSE Pro Platform showed 100% acute procedural success, 0.4% adverse event rate, and 17.9-minute mean ablation time. OMNYPULSE Platform had 82.5% freedom from arrhythmia recurrence at 12 months. Both studies support JNJ's atrial fibrillation treatment technologies.

finanznachrichten.de3 min
OCT 22
$JNJMedAI 8/10

Johnson & Johnson Reports First Real-World VARIPULSE Pro Platfor

Johnson & Johnson (JNJ) presented data from VARIPURE and Omny-IRE studies at APHRS 2026. VARIPULSE Pro showed 100% acute procedural success in 225 patients, with a 0.4% adverse event rate. OMNYPULSE Platform had 82.5% freedom from AF recurrence at 12 months. CARTO 3 System data showed lower long-term AF-related acute-care utilization compared to EnSite.

gurufocus.com2 min